Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Rating of “Hold” from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned a consensus rating of “Hold” from the eleven analysts that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $381.44.

A number of research firms have recently weighed in on MEDP. TD Cowen cut their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Truist Financial cut their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Medpace Price Performance

Shares of Medpace stock opened at $355.15 on Thursday. The business has a 50-day moving average of $342.85 and a 200-day moving average of $350.27. The company has a market capitalization of $11.04 billion, a PE ratio of 31.10, a P/E/G ratio of 1.79 and a beta of 1.36. Medpace has a 1-year low of $293.37 and a 1-year high of $459.77.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Centaurus Financial Inc. lifted its holdings in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the period. Schulhoff & Co. Inc. increased its stake in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock valued at $874,000 after purchasing an additional 30 shares in the last quarter. Lindenwold Advisors INC increased its position in shares of Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after acquiring an additional 32 shares in the last quarter. Stephens Inc. AR increased its position in shares of Medpace by 4.9% during the fourth quarter. Stephens Inc. AR now owns 752 shares of the company’s stock worth $250,000 after acquiring an additional 35 shares in the last quarter. Finally, M&T Bank Corp grew its position in Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after purchasing an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.